Citi Research issued a research report expecting SINO BIOPHARM (01177.HK) +0.030 (+1.087%) Short selling $19.73M; Ratio 21.373% to post intact 1H24 results, with earnings expected to grow by about 10% YoY due to strong sales growth of biosimilar and innovative drugs.
Higher visibility is expected in the Company's 2H24 results on increased sales of biosimilar, G-CSF and Cataplasms.
Citi Research opened an upside 30-day catalyst watch on SINO BIOPHARM, with a target price of $6.8 and rating at Buy.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2024-07-25 16:25.)
AAStocks Financial News
China's assets explosion and the high record global capital influx hit
Hong Kong Stocks Surge, Hang Seng Index Opens Up 543 Points
China's bailout policy triggers LVMH and Hermès to rise nearly 10%
Will policies boost confidence and the A-share market live up to expectations?
Check whenever you want
WikiStock APP